Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

Publisher: La Merie Publishing
Pages: 42
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0024
Release Date: February of 2016

200.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

This Competitive Intelligence Report provides a competitor evaluation in the field of approved and investigational vaccines and therapeutics against one or more serotypes of Dengue Virus for prophylaxis or treatment of Dengue fever as of February 2016. The report covers live attenuated or whole virus vaccines, recombinant subunit and DNA-based vaccines for prophylaxis of Dengue fever as well as therapeutic antibodies and other antivirals directed against Dengue Virus. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Dengue virus (DENV) is a mosquito-borne flavivirus that infects at least 390 million people per year. It is estimated that nearly half the world's population is at risk for dengue infection. The primary mosquito vector for dengue, Aedes aegypti, continues to spread widely and into new habitats due to increased urbanization and climate change.

Dengue vaccines could have beneficial individual-level effects by reducing the probability of infection given exposure to an infected mosquito. In addition, with increasing vaccine coverage in a population, vaccines could reduce the overall transmission in the entire community, even to unvaccinated people, and thus have indirect or herd effects. The first Dengue vaccine only recently has been approved in three countries and several more vaccine candidates are in the pipeline.

Therapeutic antibodies and other antiviral agents might help in the post-exposure prophylaxis and treatment of Dengue virus-infected indivivuals. Several candidates are in the development pipeline. Preclinical studies of a candidate antibody have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its continued development as a single administration for the treatment of dengue virus infection.

The report includes a compilation of currently active projects in research and development of vaccines targeting Dengue virus for prophylaxis of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines, Antibodies and Antivirals. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

Table of contents

1) Dengue Virus Vaccines:

  • Live Attenuated or Inactivated Whole-Virus Dengue Virus Vaccines
  • Recombinant Subunit Dengue Virus Vaccines
  • DNA-based Dengue Virus Vaccines
  • Others

2) Dengue Virus Therapeutic Antibodies

3) Dengue Virus Antivirals

4) Corporate Dengue Virus Vaccines, Antibodies & Antivirals R&D Pipeline



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top